Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Matthew Jenner, Louise Flanagan et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 22
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Kwee Yong, Samantha Hinsley et al.|BMC Hematology|2016Cited by 9